Consolidated Cash Flow Statement

Profit after tax

303.3

481.9

Depreciation/amortization/impairment losses/write-ups

1,037.4

1,253.5

Changes in inventories

93.4

–87.5

Changes in trade accounts receivable

139.3

–74.7

Changes in trade accounts payable

192.1

–74.3

Changes in provisions

550.9

22.7

Changes in other assets and liabilities

–216.8

–121.7

Neutralization of gain/loss on disposals of assets

–32.0

–205.7

Other non-cash income and expenses

6.1

22.6

Net cash flows from operating activities

2,073.9

1,216.7

Purchase of intangible assets

–88.0

–35.8

Purchase of property, plant and equipment

–181.1

–246.0

Acquisitions

–4.1

–84.3

Investments in financial assets

–14.6

–6.5

Disposal of non-current assets

63.6

557.3

Purchase/sale of marketable securities

10.5

–21.3

Changes in other financial assets

–370.8

–912.0

Net cash flows from investing activities

–584.4

–748.6

Dividend payments

–102.2

–84.5

Profit transfers to E. Merck KG and changes in reserves

–92.1

–233.0

Changes in liabilities to E. Merck KG

–143.2

81.5

Repayment of bonds

–500.0

–

Changes in current and non-current financial liabilities

–106.2

–37.6

Net cash flows from financing activities

–943.7

–273.6

Changes in cash and cash equivalents

545.7

194.5

Changes in cash and cash equivalents due to currency translation

1.3

–2.2

Cash and cash equivalents as of January 1 (Group balance sheet)

937.8

943.7

Plus cash and cash equivalents previously in assets held for sale

–

1.2

Cash and cash equivalents as of September 30

1,484.7

1,137.2